Skip to main content
Equibles
ELTX logo

ELTX · Elicio Therapeutics, Inc. · Metrics

Track ELTX — free

Use ELTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.56 -0.07 (-4.29%) At close · Nov 12
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”
View the 10-Q filed Nov 5, 2026
Market Cap
$44.16M
Shares
28.31M
Volume · Nov 12 232.82K Avg daily vol (3M) 320.42K

ELTX metrics

73 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.56
Market cap
$44.16M

Price action

23 metrics
Price change (1W)
+4.5%
Price change (30D)
-7.9%
Price change (3M)
-46.7%
Price change (6M)
-85.6%
Price change (YTD)
-79.5%
Price change (1Y)
-82.3%
Trailing year
Price change (5Y)
—
52-week high
$14.85
52-week low
$1.40
Change from 52-week high
-89.0%
Change from 52-week low
+16.4%
Annualized volatility
144.2%
Annualized volatility (3M)
74.8%
Implied volatility (30D)
214.3%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.7
RSI (14D)
45.3
Price vs SMA 50
-11.8%
Price vs SMA 200
-75.0%
Avg volume (3M)
319,003
Relative volume
1.1
Average dollar volume
$661,490

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
28.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
70.7×
reciprocal yield 1.4%
P / book
2.4
reciprocal yield 40.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-77.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-15

Profitability

9 metrics
Gross margin
100.0%
Operating margin
-1,031.4%
Trailing 12 months
Net margin
-1,225.9%
Gross profit (TTM)
$27.88M
Operating profit (TTM)
−$38.33M
Net income (TTM)
−$35.74M
Trailing 12 months
Diluted EPS (TTM)
$-1.83
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$9.35
Operating profit per diluted share (TTM)
$-2.02
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.88
Operating cash flow per diluted share (TTM)
$-1.90
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.24
Stock compensation per diluted share (TTM)
$0.19
Book value per share
$0.09

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$653,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+57.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-189.6%
Return on assets
-90.3%
Debt / equity
0.5
Current ratio
3.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.4
Interest coverage
-24.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$21.27M
Latest balance sheet
Cash & equivalents
$30.90M
Total assets
$39.60M
Total debt
$9.63M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$36.97M
Capital expenditures (TTM)
—
R&D (TTM)
$23.54M
SG&A (TTM)
—
Stock compensation (TTM)
$3.68M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
48
13F filer change QoQ
+1
Institutional ownership
20.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
1.5%
Private-fund adviser ownership
1.4%
Active holders' share change QoQ
+7.5%
Holder tenure
6.0
Price vs estimated holder cost
-58.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.5%

Short interest

3 metrics
Short interest
6.5%
Latest settlement · 5.9 days to cover
Days to cover
5.9d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1601485 CUSIP 28657F103 13F (30d) 44 filings 43 filers Visit website Investor relations